Seattle Genetics, Inc. (SGEN) - Financial and Strategic Analysis Review by GlobalData

VIEWS: 24 PAGES: 38

Seattle Genetics, Inc. (Seattle) is a biotechnology company engaged in the discovery and the development of monoclonal antibody-based drugs to treat cancer and autoimmune diseases. The company's lead product candidate brentuximab vedotin (SGN-35) is in the pivotal clinical trial for Hodgkin lymphoma and in Phase II clinical trials for Systemic anaplastic large cell lymphoma. Seattle has several other product candidates in various stages of clinical development.The products of the company are principally based on three technologies namely genetically engineered monoclonal antibodies, antibody-drug conjugates (ADCs) and Sugar Engineered Antibodies (SEA).

Seattle Genetics, Inc. Key Recent Developments

Aug 03, 2010 Seattle Genetics Expands Antibody-Drug Conjugate Collaboration With Genentech
Jul 27, 2010 Seattle Genetics Reports Net Loss Of $8.3 Million For Q2 2010
May 24, 2010 Seattle Genetics Appoints Charles Romp As Vice President, Sales
Apr 21, 2010 Seattle Genetics To Get Payment From Genentech Under Antibody-Drug Conjugate Collaboration
Apr 21, 2010 Seattle Genetics, Agensys Release Preclinical Data From ASG-5ME Trial

This comprehensive SWOT profile of Seattle Genetics, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company hi

More Info
									        Seattle Genetics, Inc. (SGEN) - Financial and Strategic Analysis Review

       Reference Code: GDME4301FSA                                                                                       Publication Date: AUG 2010

       21823 30th Drive SE                    Phone            +1 425 5274000                          Revenue            52 (million USD)
       Bothell, WA                            Fax              +1 425 5274001                          Net Profit         -81.68 (million USD)
       98021                                  Website          www.seagen.com                          Employees          289
       United States                          Exchange         SGEN [NASDAQ]                           Industry           Medical Equipment

      Company Overview
       Seattle Genetics, Inc. (Seattle) is a biotechnology company engaged in the discovery and the development of monoclonal
       antibody-based drugs to treat cancer and autoimmune diseases. The company's lead product candidate brentuximab vedotin
       (SGN-35) is in the pivotal clinical trial for Hodgkin lymphoma and in Phase II clinical trials for Systemic anaplastic large cell
       lymphoma. Seattle has several other product candidates in various stages of clinical development.The products of the company
       are principally based on three technologies namely genetically engineered monoclonal antibodies, antibody-drug conjugates
       (ADCs) and Sugar Engineered Antibodies (SEA).

      Key Executives                                                                  SWOT Analysis
                     Name                                   Title                     Seattle Genetics, Inc., SWOT Analysis
       Clay B. Siegall, Ph.D.                Chairman                                 Strengths                    Weaknesses

       Srinivas Akkaraju, M.D., Ph.D.        Director
                                                                                      Focused Research and               No Marketed Products
       Felix J. Baker, Ph.D.                 Director                                 Development
       Franklin M. Berger                    Director                                                                    Low Return on Equity
                                                                                      Proprietary Technologies
       David W. Gryska                       Director
       Source: Annual Report, Company Website, Primary and Secondary Research
       GlobalData
                                                                                      Opportunities                      Threats
      Share Data
       Seattle Genetics, Inc.                                                         Therapeutic Opportunities in       Intense Competition
       Share Price (USD) as on 27-Aug-2010                                  12.0      the US

                                                                           -0.90                                         Tightening of FDA’s
       EPS (USD)
                                                                                      Strong Product Pipeline            Regulatory Oversight
       Market Cap (million USD)                                            1,215

       Enterprise Value (million USD)                                           889

       Shares Outstanding (million)                                             101   Source: Annual Report, Company Website, Primary and Secondary
       Source: Annual Report, Company Website, Primary and Secondary Research         Research
       GlobalData
                                                                                      GlobalData


      Financial Performance                         
								
To top